The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Teva shares slide on generic Copaxone fears

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011

Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan.

Teva's Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news hit the market on Thursday after Israel's market closed for the weekend. Teva's New York-listed shares fell 3.8 percent on Thursday but gained 2.2 percent on Friday, ending the week at $64.91.

In a potentially major blow for Teva, the U.S. Food and Drug Administration approved the first generic version of multiple sclerosis drug Copaxone, which accounts for about half the company's profit.

The 20 mg generic drug Glatopa was developed by Sandoz, a unit of Swiss drugmaker Novartis AG, and Momenta Pharmaceuticals Inc, for treating patients with relapsing forms of the neurodegenerative disease.

Trying to minimize the damage to its own drug, Teva - the world's biggest generic drugmaker - has been shifting MS patients from a daily 20 mg dose to a three times a week 40 mg formulation. Though the patent of the higher dose expires in 2030, investors fear it will be challenged in court and possibly nullified as early as 2017.

"That is what the market is worried about. It's the fear of losing Copaxone and the realization that Teva is now under pressure to do something quick," said Excellence Nessuah analyst Gilad Alper.

He said Teva might have to abandon long-term plans of making small deals and developing its own drugs in favor of a major acquisition. Several news outlets reported on Friday that Teva was considering a bid for Mylan.

A Teva spokesman did not comment on the market speculation.

Mylan, a generic drugmaker that has moved its headquarters from the United States to the Netherlands to take advantage of lower taxes, made its own $29 billion offer to buy Perrigo 10 days ago, and its chief executive said a merger with Teva would be a bad fit.

Some shareholders of Teva echoed this view.

"Mylan would give Teva severe indigestion," said activist shareholder Benny Landa, noting Mylan was a cultural mismatch for Teva. "Teva should not be making $30 billion acquisitions, even if they promise to be accretive in the short term. Teva should be focusing on multiple sub-$10 billion ... acquisitions that will infuse the company with complementary technologies and products."

David Munno, head of research at the Sphera Global Healthcare Fund, which owns shares in Teva and Mylan, said however that Teva could afford to buy Mylan with a combination of cash, debt and equity.

"If an opportunity like Mylan were to come up ... the synergies between Teva and Mylan or Teva and another generic combination would be difficult to ignore and we would expect Teva to look at that seriously," he said.

Story Source: The above story is based on materials provided by REUTERS
Note: Materials may be edited for content and length